Form 4 for VKTX Viking Therapeutics, Inc.
Accepted 2022-01-05 00:00:00 ET · period of report 2022-01-03 · accession 0001209191-22-001986 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-01-05 | 2022-01-03+ | VKTX | Lian Brian | Pres, CEO, Dir | F - Tax | $4.77 | -62.8K | 1.89M | -3% | -$299.4K |
| D | 2022-01-05 | 2022-01-03 | VKTX | Lian Brian | Pres, CEO, Dir | A - Grant | $0.00 | +173.3K | 2.06M | +9% | $0 |
| D | 2022-01-05 | 2022-01-03 | VKTX | Lian Brian | Pres, CEO, Dir | A - Grant | $0.00 | +390.0K | 390.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.00001 per share | 2022-01-04 | F | D | 26,432 | $4.62 | 2,036,686 | D | — | — | |
| 2 | Common | Common Stock, par value $0.00001 per share | 2022-01-03 | F | D | 36,319 | $4.88 | 1,889,785 | D | — | — | (F2) Includes 1,297 shares acquired on November 19, 2021 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. |
| 3 | Common | Common Stock, par value $0.00001 per share | 2022-01-03 | A | A | 173,333 | $0.00 | 2,063,118 | D | — | — | (F3) Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. |
| 4 | Derivative | Stock Option (Right to Buy) | 2022-01-03 | A | A | 390,000 | $0.00 | 390,000 | D | $4.88 · 2023-01-03 to 2032-01-03 | 390,000 Common Stock | (F4) 25% of the shares subject to the option will vest on each anniversary of the grant date. |